Researchers from the Chinese Academy of Medical Sciences and Beijing Hospital have launched a groundbreaking early‑stage clinical trial that pairs donor natural‑killer (NK) cells with the standard chemotherapy drugs gemcitabine and S‑1 for patients with advanced pancreatic cancer. Published on December 9, 2025 in *Signal Transduction and Targeted Therapy*, the phase 1b/2 study (ChiCTR1900021764) showed that the combined treatment is safe and hints at early signs of effectiveness, prompting calls for larger trials. Pancreatic cancer remains one of the deadliest cancers, with fewer than 10 % of patients surviving five years, so fresh therapeutic approaches are urgently needed. Unlike T‑cell therapies, NK cells can attack tumor cells without prior sensitization and can be produced “off‑the‑shelf,” making them attractive for rapid clinical use. Multi‑omics analysis of patients’ blood revealed specific NK and T‑cell subsets that may predict how well patients respond, offering new insight into the immune dynamics at play. While earlier NK‑cell work has shown promise in blood cancers and liver cancer, this is among the first trials to test NK cells alongside gemcitabine + S‑1 in pancreatic cancer. The early results are encouraging and set the stage for more extensive research into NK‑cell‑based combos as a potential lifeline for a disease that has long lacked effective treatments.
Read moreGuangzhou has announced a sweeping new policy to raise the share of its fiscal budget devoted to science and technology, aiming to turn the city into a world‑class innovation hub. In the life‑sciences arena, the city is already making headlines. A home‑grown anti‑influenza drug, the world’s first to target the PB2 protein of flu‑A, has received market approval, offering a uniquely Chinese solution to seasonal outbreaks. Guangzhou Lab also launched the nation’s largest Biosafety Level‑3 laboratory and secured funding for the 1.67‑billion‑yuan “China Digital Lung” platform, a smart research centre for respiratory disease. Breakthroughs from the Guangzhou Institute of Biomedicine include the first human‑like heart grown inside a pig embryo that survived three weeks, and a new STING‑protein pathway that could protect patients from radiation‑induced tumor damage. Researchers at Sun Yat‑sen University uncovered key clues for preventing nasopharyngeal cancer, while Akeso Biosciences’ bispecific antibody ivonescimab outperformed the global benchmark drug Keytruda. Xiang Xue Life Sciences saw its TCR‑T therapy earn national breakthrough status. Beyond biotech, Guangzhou is building an all‑space unmanned‑systems network—leveraging eVTOL pioneer EHang, autonomous‑driving firms WeRide and Pony.ai, and XPeng’s flying‑car factory—to showcase future mobility. The city’s AI cluster is also rolling out embodied‑intelligence robots for manufacturing, rehabilitation and care, while massive cell‑and‑gene‑therapy platforms aim to turn scientific discoveries into market‑ready treatments. This coordinated push positions Guangzhou at the forefront of global science, technology and health innovation.
Read moreBioValley’s portal brings the latest buzz from labs worldwide, covering everything from metabolomics and tumor immunotherapy to 3D‑printed medical devices. Among the fresh breakthroughs, researchers at Southern University of Science and Technology uncovered a surprising partnership between tumor cells and lipid‑laden macrophages. Their CBX3‑SNX10‑ANO6 signaling cascade creates a hybrid cell that fuels breast‑cancer spread, opening a new therapeutic target. In a separate study, Zhejiang University of Chinese Medicine used single‑cell RNA sequencing to map the aging immune environment in osteoarthritis, revealing how immune‑cell crosstalk damages cartilage and suggesting ways to halt joint degeneration. Neuroscientists have pinpointed the structural collapse of the GPX4 protein as the trigger for ferroptosis—a form of cell death that drives early‑onset dementia and may also underlie Alzheimer’s disease—offering a fresh angle for drug development. Meanwhile, a Nature team decoded how mRNA exits the nucleus, identifying the ATP‑gated protein UAP56 as the master switch that ensures precise gene‑message export. Finally, a nanozyme engineered by Nanjing University promises real‑time monitoring and treatment of abdominal aortic aneurysms. Together, these studies illustrate how cutting‑edge biology is rapidly turning complex mechanisms into tangible health solutions.
Read more